Your browser doesn't support javascript.
loading
Trifluridine-tipiracil plus bevacizumab versus trifluridine-tipiracil monotherapy for chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis.
Aquino de Moraes, Francisco Cezar; Dantas Leite Pessôa, Felipe Dircêu; Duarte de Castro Ribeiro, Caio Henrique; Rodrigues Fernandes, Marianne; Rodríguez Burbano, Rommel Mario; Carneiro Dos Santos, Ney Pereira.
Afiliação
  • Aquino de Moraes FC; Oncology Research Center, Federal University of Pará, University Hospital João de Barros de Barreto. Rua dos Mundurucus, nº4487, Belem, 66073-005, PA, Brazil. Francisco.cezar2205@gmail.com.
  • Dantas Leite Pessôa FD; School of Medicine, University of São Paulo - USP, São Paulo, 01246-903, Brazil.
  • Duarte de Castro Ribeiro CH; School of Medicine, Federal University of Pará, Belem, 66075-110, Brazil.
  • Rodrigues Fernandes M; Oncology Research Center, Federal University of Pará, University Hospital João de Barros de Barreto. Rua dos Mundurucus, nº4487, Belem, 66073-005, PA, Brazil.
  • Rodríguez Burbano RM; Ophir Loyola Hospital, Belém, 66063-240, PA, Brazil.
  • Carneiro Dos Santos NP; Oncology Research Center, Federal University of Pará, University Hospital João de Barros de Barreto. Rua dos Mundurucus, nº4487, Belem, 66073-005, PA, Brazil.
BMC Cancer ; 24(1): 674, 2024 Jun 03.
Article em En | MEDLINE | ID: mdl-38825703
ABSTRACT
Colorectal cancer is the leading cause of cancer death worldwide. The first and second lines of treatment for metastatic colorectal cancer (mCRC) include chemotherapy based on 5-fluorouracil. However, treatment following progression on the first and second line is still unclear. We searched PubMed, Scopus, Cochrane, and Web of Science databases for studies investigating the use of trifluridine-tipiracil with bevacizumab versus trifluridine-tipiracil alone for mCRC. We used RStudio version 4.2.3; and we considered p < 0.05 significant. Seven studies and 1,182 patients were included - 602 (51%) received trifluridine-tipiracil plus bevacizumab. Compared with control, the progression-free survival (PFS) (HR 0.52; 95% CI 0.42-0.63; p < 0.001) and overall survival (OS) (HR 0.61; 95% CI 0.52-0.70; p < 0.001) were significantly higher with bevacizumab. The objective response rate (ORR) (RR 3.14; 95% CI 1.51-6.51; p = 0.002) and disease control rate (DCR) (RR 1.66; 95% CI 1.28-2.16; p = 0.0001) favored the intervention. Regarding adverse events, the intervention had a higher rate of neutropenia (RR 1.38; 95% CI 1.19-1.59; p = 0.00001), whereas the monotherapy group had a higher risk of anemia (RR 0.60; 95% CI 0.44-0.82; p = 0.001). Our results support that the addition of bevacizumab is associated with a significant benefit in PFS, OS, ORR and DCR.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirrolidinas / Timina / Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica / Trifluridina / Combinação de Medicamentos / Bevacizumab Limite: Humans Idioma: En Revista: BMC Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirrolidinas / Timina / Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica / Trifluridina / Combinação de Medicamentos / Bevacizumab Limite: Humans Idioma: En Revista: BMC Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido